PPIDT00237
Drug Information
| Name | Lanreotide |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06791 |
| Type | small molecule |
| Indication | Lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy.[L41115] It is also indicated in the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.[L41115] Lanreotide is additionally indicated for the treatment of adults with carcinoid syndrome - when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.[L41115] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for suspension, extended release | Intramuscular |
30 mg/2mL
|
| Injection, solution | Intramuscular |
60 mg
|
| Injection, solution | Intramuscular |
90 mg
|
| Injection, suspension, extended release | Intramuscular |
120 mg
|
| Injection, suspension, extended release | Intramuscular |
60 mg
|
| Injection, powder, for suspension | Intramuscular |
|
| Powder | Not applicable |
1 g/1g
|
| Injection, solution | — |
120 MG
|
| Injection, solution | — |
60 MG
|
| Injection, solution | — |
90 MG
|
| Solution | Subcutaneous |
6000000 mg
|
| Injection, solution | — |
24.6 mg/100mg
|
| Solution | Subcutaneous |
60.000 mg
|
| Solution, gel forming, extended release | Subcutaneous |
120 mg / syr
|
| Solution, gel forming, extended release | Subcutaneous |
60 mg / syr
|
| Solution, gel forming, extended release | Subcutaneous |
90 mg / syr
|
| Injection, solution | Parenteral |
|
| Injection, solution | Parenteral |
120 mg
|
| Solution | Subcutaneous |
120 mg
|
| Injection, solution | Parenteral |
60 mg
|
| Injection | Subcutaneous |
60 mg/0.5ml
|
| Solution | Subcutaneous |
60 mg
|
| Injection, solution | Parenteral |
90 mg
|
| Injection | Subcutaneous |
90 mg/0.5ml
|
| Solution | Subcutaneous |
90 mg
|
| Injection, solution | Subcutaneous |
120 mg
|
| Injection, solution | Subcutaneous |
60 mg
|
| Injection, solution | Subcutaneous |
90 mg
|
| Injection | Subcutaneous |
120 mg/0.5mL
|
| Injection | Subcutaneous |
60 mg/0.2mL
|
| Injection | Subcutaneous |
90 mg/0.3mL
|
Target Information